Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing open label study is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of testing. At baseline, prior to dosing, the subject’s Modified Ichthyosis Area of Severity Index was 18. Following six weeks of dosing with QRX003, the subject’s MIASI had been reduced to 4. In addition, the Investigator’s Global Assessment of disease severity prior to dosing classified the subject as ‘moderate’. After six weeks of dosing with QRX003, the IGA for the subject was classified as ‘mild’. The subject’s pruritus or itch assessment at baseline was 7 out of a maximum of 11 based on the Worst Itch Numeric Rating Scale and was reduced to 4 at the treatment midpoint. Finally, the patient satisfaction scores across assessed metrics were highly positive. No safety concerns were reported for the subject during this initial testing period. In addition, after the initial 12 days of dosing in Quoin’s ongoing 12-week Investigator Pediatric Study, a significant improvement was observed in the skin area treated with QRX003 versus the non-treated area. Specifically, at baseline prior to dosing with QRX003, the IGA assessment of the subject’s skin was classified as ‘severe’. After 12 days of treatment with QRX003, this was improved to ‘mild-moderate’, representing a very rapid improvement in skin appearance. There have been no adverse events or safety concerns reported to date.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QNRX:
- Quoin Pharmaceuticals files to sell 19.23M ordinary shares
- Quoin Pharmaceuticals Annual Meeting Approves Key Amendments
- Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges
- Quoin Pharmaceuticals reports Q3 EPS ($1.63), consensus (49c)
- Quoin Pharmaceuticals sees cash runway into late 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
